Videos
Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective
NAFLD/NASH as a metabolic disease: improving patients outcomes
NAFLD / NASH as a metabolic disease: improving patients outcomes
The course of liver histology and morbi-mortality in NAFLD / NASH
Defining comprehensive models of care for NAFLD Liver health specialists
From number-one liver disease to multi-system disease: NASH, a major unmet clinical need
Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany
Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)
Management of Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: Weight gain with PPAR-γ Agonists
Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)
Management of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
Microvesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. Rautou
NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.
The role of a global holistic approach in NASH management: important messages
The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician
What can we expect from PPAR agonists in the treatment of NASH?
Prof Jordi Gracia-Sancho, Barcelona, discusses the need to develop new therapeutic approaches that target more than one molecular pathway for chronic liver disease.
Prof Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston
Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.
Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.
Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting.
Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston
Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston. She sees a lot of hope in new clinical trials and new biomarkers.
Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.
Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH
Why are PPAR agonists a promising option for the management of NASH ?
Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH
An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
Learn more about the burden of the disease, Prof Sven Francque, Belgium